Skip to main content

Table 1 Characteristics of patients in the study

From: T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles

Patient

Ethnicity

HLA-DRB1 genotype

ACPA

Disease duration (years)

Treatment

C-reactive proteina (mg/l)

Representation

RA1

Caucasian

03,0401

+

6

M, S

8

Figure 1

RA2

Caucasian

03, 0401

+

< 1

Nil

3

Figures 1 to 5

RA3

Caucasian/Pacific Islander

0403, 0405

-

< 1

M, S, H

3

Figure 1

RA4

Caucasian

0401, 0404

+

< 1

L

11

Figures 1 to 5

RA5

Caucasian

0404, 1302

+

1

M, S, H

2

Figure 1

RA6

Caucasian

0401 13

+

> 5

M, H

1

Figures 1 to 5

RA7

Asian

0405

-

1

M

1

Figures 1 to 5

RA8

Caucasian

0401, 0404

+

> 5

L, H, S

22

Figures 1 to 5

RA9

Caucasian

0103, 0101

+

< 1

Nil

4

Figures 1 to 5

RA10

Caucasian

01, 1302

+

5

H

10

Figures 1 to 5

RA11

Caucasian

04, 0301

-

4

M, S, H

3

Figures 1 to 5

RA12

Caucasian

0401

+

0

Nil

45

Figures 1 to 5

RA13

Caucasian

0101, 1301

-

> 5

M

20

Figures 1 to 6

RA14

Caucasian

0408, 11

+

> 5

M, S, H

4.6

Figures 1 to 6

RA15

Caucasian

0401, 0408

+

0

Nil

1

Figures 1 to 6

RA16

Caucasian

0101, 0408

+

0

Nil

6

Figures 1 to 6

RA17

Caucasian

0401, 03

+

> 5

M, A

33

Figure 6

RA18

Caucasian

0401, 03

+

3

M

2

Figures 1 to 5

RA19

Caucasian

0101, 0103

+

2

M, S, H

5.3

Figures 1 to 5

RA20

Caucasian

0401, 1501

+

2

-

9.9

Figures 1 to 5

RA21

Caucasian

0401, 0101

+

> 5

M, P

2

Figures 1 to 5

HC1

Caucasian

01

-

   

Figures 1 to 5

HC2

Caucasian

03, 04

-

   

Figures 1 to 5

HC3

Caucasian

0401, 0701

-

   

Figures 1 to 5

HC4

Caucasian

0101, 08

-

   

Figures 1 to 5

HC5

Caucasian

1301, 0401

-

   

Figures 1 to 6

HC6

Caucasian

0401, 1301

-

   

Figures 1 to 6

  1. A, abatacept; ACPA, anti-citrullinated peptide antibody; H, hydroxychloroquine; L, leflunomide; M, methotrexate; S, sulfasalazine; P, prednisone. For rheumatoid arthritis (RA) patients, mean age is 50 (range 22 to 65), 90% female; for healthy control (HC) individuals, mean age is 38 (40 to 45), 50% female. aMeasured at the time of blood withdrawal for peptide response.